Cayman
Showing 42151–42300 of 45550 results
-
Antigen: synthetic peptide within the region of human TIP60 amino acids 480-530 • Host: rabbit • Cross Reactivity: (+) human (isoform CRA_b), chimpanzee, orangutan, equine, canine, mouse, ovine, rat, opossum, zebrafish, and Xenopus TIP60 • Application(s): IHC and WB • TIP60 belongs to the MYST family of HATs. It is a catalytic subunit of the NuA4 HAT complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A.
Brand:CaymanSKU:13789- 1 eaAvailable on backorder
Antigen: synthetic peptide within the region of human TIP60 amino acids 480-530 • Host: rabbit • Cross Reactivity: (+) human (isoform CRA_b), chimpanzee, orangutan, equine, canine, mouse, ovine, rat, opossum, zebrafish, and Xenopus TIP60 • Application(s): IHC and WB • TIP60 belongs to the MYST family of HATs. It is a catalytic subunit of the NuA4 HAT complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A.
Brand:CaymanSKU:13789- 1 eaTipifarnib is a nonpeptidomimetic, CAAX-competitive inhibitor of farnesyltransferase (IC50 = 0.86 nM).{33516} It prevents farnesylation of Ras GTPases and has shown potent efficacy in various in vitro and in vivo tumor models.{21247,21707}
Brand:CaymanSKU:11747 - 1 mgAvailable on backorder
Tipifarnib is a nonpeptidomimetic, CAAX-competitive inhibitor of farnesyltransferase (IC50 = 0.86 nM).{33516} It prevents farnesylation of Ras GTPases and has shown potent efficacy in various in vitro and in vivo tumor models.{21247,21707}
Brand:CaymanSKU:11747 - 10 mgAvailable on backorder
Tipifarnib is a nonpeptidomimetic, CAAX-competitive inhibitor of farnesyltransferase (IC50 = 0.86 nM).{33516} It prevents farnesylation of Ras GTPases and has shown potent efficacy in various in vitro and in vivo tumor models.{21247,21707}
Brand:CaymanSKU:11747 - 5 mgAvailable on backorder
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase.{40279} It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine (Item No. 21366), a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.{40281}
Brand:CaymanSKU:23319 - 1 mgAvailable on backorder
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase.{40279} It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine (Item No. 21366), a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.{40281}
Brand:CaymanSKU:23319 - 10 mgAvailable on backorder
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase.{40279} It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine (Item No. 21366), a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.{40281}
Brand:CaymanSKU:23319 - 25 mgAvailable on backorder
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase.{40279} It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine (Item No. 21366), a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.{40281}
Brand:CaymanSKU:23319 - 5 mgAvailable on backorder
Tiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 2.7 µM with human recombinant PAI-1).{34136} In rat thrombosis models, the time to occlusion is longer, carotid blood flow reduction is partially prevented, and thrombus size is smaller compared with control rats.{34136,34137}
Brand:CaymanSKU:9000450 - 1 mgAvailable on backorder
Tiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 2.7 µM with human recombinant PAI-1).{34136} In rat thrombosis models, the time to occlusion is longer, carotid blood flow reduction is partially prevented, and thrombus size is smaller compared with control rats.{34136,34137}
Brand:CaymanSKU:9000450 - 10 mgAvailable on backorder
Tiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 2.7 µM with human recombinant PAI-1).{34136} In rat thrombosis models, the time to occlusion is longer, carotid blood flow reduction is partially prevented, and thrombus size is smaller compared with control rats.{34136,34137}
Brand:CaymanSKU:9000450 - 5 mgAvailable on backorder
Tiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 2.7 µM with human recombinant PAI-1).{34136} In rat thrombosis models, the time to occlusion is longer, carotid blood flow reduction is partially prevented, and thrombus size is smaller compared with control rats.{34136,34137}
Brand:CaymanSKU:9000450 - 50 mgAvailable on backorder
Tipranavir is a potent, orally bioavailable nonpeptidic HIV aspartyl protease inhibitor (Ki = < 1 nM) that prevents cleavage and thus activation of functional HIV cleaved proteins.{34181,34180} Formulations containing tipranavir, in combination with other HIV treatments, are effective against multidrug resistant viruses and are used in the treatment of HIV infection progression in patients who have not responded well to initial treatments.{34179}
Brand:CaymanSKU:21028 -Out of stock
Tipranavir is a potent, orally bioavailable nonpeptidic HIV aspartyl protease inhibitor (Ki = < 1 nM) that prevents cleavage and thus activation of functional HIV cleaved proteins.{34181,34180} Formulations containing tipranavir, in combination with other HIV treatments, are effective against multidrug resistant viruses and are used in the treatment of HIV infection progression in patients who have not responded well to initial treatments.{34179}
Brand:CaymanSKU:21028 -Out of stock
Tipranavir-d4 is intended for use as an internal standard for the quantification of tipranavir (Item No. 21028) by GC- or LC-MS. Tipranavir is a potent, orally bioavailable nonpeptidic HIV aspartyl protease inhibitor (Ki = <1 nM) that prevents cleavage and thus activation of functional HIV-cleaved proteins.{34180,34181} Formulations containing tipranavir, in combination with other HIV treatments, are effective against multidrug resistant viruses and are used in the treatment of HIV infection progression in patients who have not responded well to initial treatments.
Brand:CaymanSKU:28907 - 1 mgAvailable on backorder
Poly(ADP-ribose) polymerase 1 (PARP1) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.{27086,27088,27087} TIQ-A is a PARP1 inhibitor (IC50 = 450 nM in cultured mouse cortical neurons).{27086} It displays neuroprotective effects in cultured mouse cortical neurons injured by oxygen-glucose deprivation (IC50 = 0.15 µM). TIQ-A has been used to inhibit eosinophilic infiltration into airways of OVA-challenged mice and to induce the regression of atherosclerotic plaques in high-fat fed apolipoprotein E(-/-) mice.{27088,27087}
Brand:CaymanSKU:-Poly(ADP-ribose) polymerase 1 (PARP1) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.{27086,27088,27087} TIQ-A is a PARP1 inhibitor (IC50 = 450 nM in cultured mouse cortical neurons).{27086} It displays neuroprotective effects in cultured mouse cortical neurons injured by oxygen-glucose deprivation (IC50 = 0.15 µM). TIQ-A has been used to inhibit eosinophilic infiltration into airways of OVA-challenged mice and to induce the regression of atherosclerotic plaques in high-fat fed apolipoprotein E(-/-) mice.{27088,27087}
Brand:CaymanSKU:-Poly(ADP-ribose) polymerase 1 (PARP1) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.{27086,27088,27087} TIQ-A is a PARP1 inhibitor (IC50 = 450 nM in cultured mouse cortical neurons).{27086} It displays neuroprotective effects in cultured mouse cortical neurons injured by oxygen-glucose deprivation (IC50 = 0.15 µM). TIQ-A has been used to inhibit eosinophilic infiltration into airways of OVA-challenged mice and to induce the regression of atherosclerotic plaques in high-fat fed apolipoprotein E(-/-) mice.{27088,27087}
Brand:CaymanSKU:-Poly(ADP-ribose) polymerase 1 (PARP1) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.{27086,27088,27087} TIQ-A is a PARP1 inhibitor (IC50 = 450 nM in cultured mouse cortical neurons).{27086} It displays neuroprotective effects in cultured mouse cortical neurons injured by oxygen-glucose deprivation (IC50 = 0.15 µM). TIQ-A has been used to inhibit eosinophilic infiltration into airways of OVA-challenged mice and to induce the regression of atherosclerotic plaques in high-fat fed apolipoprotein E(-/-) mice.{27088,27087}
Brand:CaymanSKU:-Tirapazamine is a hypoxia-activated anticancer agent.{46027} It is converted to an oxidizing radical under hypoxic conditions and can induce single- and double-strand breaks in DNA, formation of trapped topoisomerase I- and II-DNA complexes, and other chromosomal aberrations, leading to cytotoxicity.{46027,46028,46029} Tirapazamine induces hypoxia-enhanced cytotoxicity in DT40 cells (IC50s = 1.02 and 4.34 μM in hypoxic and normoxic conditions, respectively).{46029} It also induces cytotoxicity in HT-1080 and A549 cells in a concentration-dependent manner under hypoxic conditions.{46027} In vivo, tirapazamine sensitizes tumors to cisplatin (Item No. 13119) in a mouse RIF-1 fibrosarcoma tumor model.{46030} Tirapazamine (0.08 mmol/kg) also sensitizes tumors to fractionated irradiation in a FaDu hypopharyngeal squamous cell carcinoma mouse xenograft model.{46031}
Brand:CaymanSKU:25981 - 10 mgAvailable on backorder
Tirapazamine is a hypoxia-activated anticancer agent.{46027} It is converted to an oxidizing radical under hypoxic conditions and can induce single- and double-strand breaks in DNA, formation of trapped topoisomerase I- and II-DNA complexes, and other chromosomal aberrations, leading to cytotoxicity.{46027,46028,46029} Tirapazamine induces hypoxia-enhanced cytotoxicity in DT40 cells (IC50s = 1.02 and 4.34 μM in hypoxic and normoxic conditions, respectively).{46029} It also induces cytotoxicity in HT-1080 and A549 cells in a concentration-dependent manner under hypoxic conditions.{46027} In vivo, tirapazamine sensitizes tumors to cisplatin (Item No. 13119) in a mouse RIF-1 fibrosarcoma tumor model.{46030} Tirapazamine (0.08 mmol/kg) also sensitizes tumors to fractionated irradiation in a FaDu hypopharyngeal squamous cell carcinoma mouse xenograft model.{46031}
Brand:CaymanSKU:25981 - 100 mgAvailable on backorder
Tirapazamine is a hypoxia-activated anticancer agent.{46027} It is converted to an oxidizing radical under hypoxic conditions and can induce single- and double-strand breaks in DNA, formation of trapped topoisomerase I- and II-DNA complexes, and other chromosomal aberrations, leading to cytotoxicity.{46027,46028,46029} Tirapazamine induces hypoxia-enhanced cytotoxicity in DT40 cells (IC50s = 1.02 and 4.34 μM in hypoxic and normoxic conditions, respectively).{46029} It also induces cytotoxicity in HT-1080 and A549 cells in a concentration-dependent manner under hypoxic conditions.{46027} In vivo, tirapazamine sensitizes tumors to cisplatin (Item No. 13119) in a mouse RIF-1 fibrosarcoma tumor model.{46030} Tirapazamine (0.08 mmol/kg) also sensitizes tumors to fractionated irradiation in a FaDu hypopharyngeal squamous cell carcinoma mouse xenograft model.{46031}
Brand:CaymanSKU:25981 - 250 mgAvailable on backorder
Tirapazamine is a hypoxia-activated anticancer agent.{46027} It is converted to an oxidizing radical under hypoxic conditions and can induce single- and double-strand breaks in DNA, formation of trapped topoisomerase I- and II-DNA complexes, and other chromosomal aberrations, leading to cytotoxicity.{46027,46028,46029} Tirapazamine induces hypoxia-enhanced cytotoxicity in DT40 cells (IC50s = 1.02 and 4.34 μM in hypoxic and normoxic conditions, respectively).{46029} It also induces cytotoxicity in HT-1080 and A549 cells in a concentration-dependent manner under hypoxic conditions.{46027} In vivo, tirapazamine sensitizes tumors to cisplatin (Item No. 13119) in a mouse RIF-1 fibrosarcoma tumor model.{46030} Tirapazamine (0.08 mmol/kg) also sensitizes tumors to fractionated irradiation in a FaDu hypopharyngeal squamous cell carcinoma mouse xenograft model.{46031}
Brand:CaymanSKU:25981 - 50 mgAvailable on backorder
Tirasemtiv is an activator of the fast skeletal troponin complex.{36966} It selectively binds to purified fast skeletal troponin complex (Kd = 40 nM) over slow skeletal (Kd = 3,800 nM) and cardiac troponin complexes. Tirasemtiv (20 μM) slows the rate of calcium release from the fast skeletal troponin complex. It increases the ATPase activity of isolated rabbit fast skeletal myofibrils at a fixed calcium concentration (EC50 = 390 nM) and sensitizes skinned fast skeletal muscle fibers isolated from human and rabbit to calcium in a concentration-dependent manner. Tirasemtiv increases in situ extensor digitorum longus (EDL) muscle force and forelimb grip strength in a rat model of myasthenia gravis. It also increases forelimb grip strength, grid hang test performance, and rotarod performance in a mouse model of amyotrophic lateral sclerosis (ALS) when administered at a dose of 10 mg/kg.{36967}
Brand:CaymanSKU:26075 - 10 mgAvailable on backorder
Tirasemtiv is an activator of the fast skeletal troponin complex.{36966} It selectively binds to purified fast skeletal troponin complex (Kd = 40 nM) over slow skeletal (Kd = 3,800 nM) and cardiac troponin complexes. Tirasemtiv (20 μM) slows the rate of calcium release from the fast skeletal troponin complex. It increases the ATPase activity of isolated rabbit fast skeletal myofibrils at a fixed calcium concentration (EC50 = 390 nM) and sensitizes skinned fast skeletal muscle fibers isolated from human and rabbit to calcium in a concentration-dependent manner. Tirasemtiv increases in situ extensor digitorum longus (EDL) muscle force and forelimb grip strength in a rat model of myasthenia gravis. It also increases forelimb grip strength, grid hang test performance, and rotarod performance in a mouse model of amyotrophic lateral sclerosis (ALS) when administered at a dose of 10 mg/kg.{36967}
Brand:CaymanSKU:26075 - 25 mgAvailable on backorder
Tirasemtiv is an activator of the fast skeletal troponin complex.{36966} It selectively binds to purified fast skeletal troponin complex (Kd = 40 nM) over slow skeletal (Kd = 3,800 nM) and cardiac troponin complexes. Tirasemtiv (20 μM) slows the rate of calcium release from the fast skeletal troponin complex. It increases the ATPase activity of isolated rabbit fast skeletal myofibrils at a fixed calcium concentration (EC50 = 390 nM) and sensitizes skinned fast skeletal muscle fibers isolated from human and rabbit to calcium in a concentration-dependent manner. Tirasemtiv increases in situ extensor digitorum longus (EDL) muscle force and forelimb grip strength in a rat model of myasthenia gravis. It also increases forelimb grip strength, grid hang test performance, and rotarod performance in a mouse model of amyotrophic lateral sclerosis (ALS) when administered at a dose of 10 mg/kg.{36967}
Brand:CaymanSKU:26075 - 5 mgAvailable on backorder
Tirasemtiv is an activator of the fast skeletal troponin complex.{36966} It selectively binds to purified fast skeletal troponin complex (Kd = 40 nM) over slow skeletal (Kd = 3,800 nM) and cardiac troponin complexes. Tirasemtiv (20 μM) slows the rate of calcium release from the fast skeletal troponin complex. It increases the ATPase activity of isolated rabbit fast skeletal myofibrils at a fixed calcium concentration (EC50 = 390 nM) and sensitizes skinned fast skeletal muscle fibers isolated from human and rabbit to calcium in a concentration-dependent manner. Tirasemtiv increases in situ extensor digitorum longus (EDL) muscle force and forelimb grip strength in a rat model of myasthenia gravis. It also increases forelimb grip strength, grid hang test performance, and rotarod performance in a mouse model of amyotrophic lateral sclerosis (ALS) when administered at a dose of 10 mg/kg.{36967}
Brand:CaymanSKU:26075 - 50 mgAvailable on backorder
Tiratricol is a metabolite of 3,3′,5-triiodo-L-thyronine (Item No. 16028) and an agonist of the thyroid hormone receptors TRα and TRβ (EC50s = 1.81 and 4.13 nM, respectively, in reporter assays).{45575} In vivo, tiratricol (50 or 400 ng/g) stimulates cerebellar Purkinje cell dendritogenesis and cortical myelination in Mct8/Oatp1c1 double knockout mice.{45574} It reduces goiter induced by methimazole (Item No. 23718) in rats when administered at a dose of 25 μg per animal.{45572} Tiratricol also decreases toll-like receptor 2 (TLR2) levels and the phosphorylation of Akt and MAPK in HEK-Blue™ cells expressing human TLR2 and reduces liver tissue necrosis in a mouse model of hepatitis induced by concanavalin A (Item No. 14951).{45573}.
Brand:CaymanSKU:28729 - 1 gAvailable on backorder
Tiratricol is a metabolite of 3,3′,5-triiodo-L-thyronine (Item No. 16028) and an agonist of the thyroid hormone receptors TRα and TRβ (EC50s = 1.81 and 4.13 nM, respectively, in reporter assays).{45575} In vivo, tiratricol (50 or 400 ng/g) stimulates cerebellar Purkinje cell dendritogenesis and cortical myelination in Mct8/Oatp1c1 double knockout mice.{45574} It reduces goiter induced by methimazole (Item No. 23718) in rats when administered at a dose of 25 μg per animal.{45572} Tiratricol also decreases toll-like receptor 2 (TLR2) levels and the phosphorylation of Akt and MAPK in HEK-Blue™ cells expressing human TLR2 and reduces liver tissue necrosis in a mouse model of hepatitis induced by concanavalin A (Item No. 14951).{45573}.
Brand:CaymanSKU:28729 - 100 mgAvailable on backorder
Tiratricol is a metabolite of 3,3′,5-triiodo-L-thyronine (Item No. 16028) and an agonist of the thyroid hormone receptors TRα and TRβ (EC50s = 1.81 and 4.13 nM, respectively, in reporter assays).{45575} In vivo, tiratricol (50 or 400 ng/g) stimulates cerebellar Purkinje cell dendritogenesis and cortical myelination in Mct8/Oatp1c1 double knockout mice.{45574} It reduces goiter induced by methimazole (Item No. 23718) in rats when administered at a dose of 25 μg per animal.{45572} Tiratricol also decreases toll-like receptor 2 (TLR2) levels and the phosphorylation of Akt and MAPK in HEK-Blue™ cells expressing human TLR2 and reduces liver tissue necrosis in a mouse model of hepatitis induced by concanavalin A (Item No. 14951).{45573}.
Brand:CaymanSKU:28729 - 50 mgAvailable on backorder
Tiratricol is a metabolite of 3,3′,5-triiodo-L-thyronine (Item No. 16028) and an agonist of the thyroid hormone receptors TRα and TRβ (EC50s = 1.81 and 4.13 nM, respectively, in reporter assays).{45575} In vivo, tiratricol (50 or 400 ng/g) stimulates cerebellar Purkinje cell dendritogenesis and cortical myelination in Mct8/Oatp1c1 double knockout mice.{45574} It reduces goiter induced by methimazole (Item No. 23718) in rats when administered at a dose of 25 μg per animal.{45572} Tiratricol also decreases toll-like receptor 2 (TLR2) levels and the phosphorylation of Akt and MAPK in HEK-Blue™ cells expressing human TLR2 and reduces liver tissue necrosis in a mouse model of hepatitis induced by concanavalin A (Item No. 14951).{45573}.
Brand:CaymanSKU:28729 - 500 mgAvailable on backorder
Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; IC50 = 5 nM in a radioligand binding assay).{37214} It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 μg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis.{37215} Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.{37216}
Brand:CaymanSKU:23392 - 1 mgAvailable on backorder
Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; IC50 = 5 nM in a radioligand binding assay).{37214} It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 μg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis.{37215} Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.{37216}
Brand:CaymanSKU:23392 - 10 mgAvailable on backorder
Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; IC50 = 5 nM in a radioligand binding assay).{37214} It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 μg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis.{37215} Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.{37216}
Brand:CaymanSKU:23392 - 5 mgAvailable on backorder
MET is a proto-oncogene that encodes the hepatocyte growth factor receptor c-Met. The receptor has normal roles in morphogenesis, migration, apoptosis, and angiogenesis.{23657} Dysregulation of c-Met occurs in many types of cancer.{23657} Tivantinib is a staurosporine (Item No. 81590) derivative that binds to dephosphorylated c-Met kinase, yet its mechanism of action is not known.{27930} Tivantinib has been tested in clinical studies for its ability to selectively inhibit c-Met.{27930} However, it can promote mitotic arrest and apoptosis of various human tumor cell lines (EC50s ranging from 60-600 nM) through mechanisms independent of its ability to bind c-Met.{27930} Tivantinib has been reported to bind directly to the colchicine binding site of tubulin, reducing tubulin polymerization in cells and in mouse xenograft tumors in vivo.{27931}
Brand:CaymanSKU:-Out of stock
MET is a proto-oncogene that encodes the hepatocyte growth factor receptor c-Met. The receptor has normal roles in morphogenesis, migration, apoptosis, and angiogenesis.{23657} Dysregulation of c-Met occurs in many types of cancer.{23657} Tivantinib is a staurosporine (Item No. 81590) derivative that binds to dephosphorylated c-Met kinase, yet its mechanism of action is not known.{27930} Tivantinib has been tested in clinical studies for its ability to selectively inhibit c-Met.{27930} However, it can promote mitotic arrest and apoptosis of various human tumor cell lines (EC50s ranging from 60-600 nM) through mechanisms independent of its ability to bind c-Met.{27930} Tivantinib has been reported to bind directly to the colchicine binding site of tubulin, reducing tubulin polymerization in cells and in mouse xenograft tumors in vivo.{27931}
Brand:CaymanSKU:-Out of stock
MET is a proto-oncogene that encodes the hepatocyte growth factor receptor c-Met. The receptor has normal roles in morphogenesis, migration, apoptosis, and angiogenesis.{23657} Dysregulation of c-Met occurs in many types of cancer.{23657} Tivantinib is a staurosporine (Item No. 81590) derivative that binds to dephosphorylated c-Met kinase, yet its mechanism of action is not known.{27930} Tivantinib has been tested in clinical studies for its ability to selectively inhibit c-Met.{27930} However, it can promote mitotic arrest and apoptosis of various human tumor cell lines (EC50s ranging from 60-600 nM) through mechanisms independent of its ability to bind c-Met.{27930} Tivantinib has been reported to bind directly to the colchicine binding site of tubulin, reducing tubulin polymerization in cells and in mouse xenograft tumors in vivo.{27931}
Brand:CaymanSKU:-Out of stock
Tivozanib is an orally available, selective VEGFR inhibitor with IC50 values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively.{19939,32739} It can also inhibit c-Kit and PDGFRβ with IC50 values of 1.63 and 1.72 nM, respectively.{32739} When administered to athymic rats, tivozanib was shown to decrease the microvessel density within tumor xenografts and attenuate VEGFR2 phosphorylation levels in tumor endothelium.{32739} It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer.{32739}
Brand:CaymanSKU:-Available on backorder
Tivozanib is an orally available, selective VEGFR inhibitor with IC50 values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively.{19939,32739} It can also inhibit c-Kit and PDGFRβ with IC50 values of 1.63 and 1.72 nM, respectively.{32739} When administered to athymic rats, tivozanib was shown to decrease the microvessel density within tumor xenografts and attenuate VEGFR2 phosphorylation levels in tumor endothelium.{32739} It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer.{32739}
Brand:CaymanSKU:-Available on backorder
Tivozanib is an orally available, selective VEGFR inhibitor with IC50 values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively.{19939,32739} It can also inhibit c-Kit and PDGFRβ with IC50 values of 1.63 and 1.72 nM, respectively.{32739} When administered to athymic rats, tivozanib was shown to decrease the microvessel density within tumor xenografts and attenuate VEGFR2 phosphorylation levels in tumor endothelium.{32739} It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer.{32739}
Brand:CaymanSKU:-Available on backorder
Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.{39278} Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.{39279} Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.{39280,39281}
Brand:CaymanSKU:-Out of stock
Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.{39278} Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.{39279} Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.{39280,39281}
Brand:CaymanSKU:-Out of stock
Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.{39278} Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.{39279} Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.{39280,39281}
Brand:CaymanSKU:-Out of stock
Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.{39278} Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.{39279} Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.{39280,39281}
Brand:CaymanSKU:-Out of stock
Tizanidine-d4 is intended for use as an internal standard for the quantification of tizanidine (Item No. 16477) by GC- or LC-MS. Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.{39278} Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.{39279} Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.{39280,39281}
Brand:CaymanSKU:26521 - 1 mgAvailable on backorder
Tizanidine-d4 is intended for use as an internal standard for the quantification of tizanidine (Item No. 16477) by GC- or LC-MS. Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.{39278} Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.{39279} Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.{39280,39281}
Brand:CaymanSKU:26521 - 500 µgAvailable on backorder
Tizoxanide is an active metabolite of the antiparasitic nitazoxanide (Item No. 13692).{17926} Tizoxanide is formed from nitazoxanide via deacetylation of nitazoxanide in the stomach. It is active against M. tuberculosis (MIC = 16 µg/ml). It also reduces the growth of the disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), inhibits influenza A replication (EC50s = 0.3-1 μM), and inhibits hepatitis B and hepatitis C virus replication (EC50 = 0.15 μM for both).{19983,19984,19985}
Brand:CaymanSKU:-Tizoxanide is an active metabolite of the antiparasitic nitazoxanide (Item No. 13692).{17926} Tizoxanide is formed from nitazoxanide via deacetylation of nitazoxanide in the stomach. It is active against M. tuberculosis (MIC = 16 µg/ml). It also reduces the growth of the disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), inhibits influenza A replication (EC50s = 0.3-1 μM), and inhibits hepatitis B and hepatitis C virus replication (EC50 = 0.15 μM for both).{19983,19984,19985}
Brand:CaymanSKU:-Tizoxanide is an active metabolite of the antiparasitic nitazoxanide (Item No. 13692).{17926} Tizoxanide is formed from nitazoxanide via deacetylation of nitazoxanide in the stomach. It is active against M. tuberculosis (MIC = 16 µg/ml). It also reduces the growth of the disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), inhibits influenza A replication (EC50s = 0.3-1 μM), and inhibits hepatitis B and hepatitis C virus replication (EC50 = 0.15 μM for both).{19983,19984,19985}
Brand:CaymanSKU:-Tizoxanide is an active metabolite of the antiparasitic nitazoxanide (Item No. 13692).{17926} Tizoxanide is formed from nitazoxanide via deacetylation of nitazoxanide in the stomach. It is active against M. tuberculosis (MIC = 16 µg/ml). It also reduces the growth of the disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), inhibits influenza A replication (EC50s = 0.3-1 μM), and inhibits hepatitis B and hepatitis C virus replication (EC50 = 0.15 μM for both).{19983,19984,19985}
Brand:CaymanSKU:-Tizoxanide-d4 is intended for use as an internal standard for the quantification of tizoxanide (Item No. 13693) by GC- or LC-MS. Tizoxanide is an active metabolite of the antiparasitic nitazoxanide (Item No. 13692).{17926} Tizoxanide is formed from nitazoxanide via deacetylation of nitazoxanide in the stomach. It is active against M. tuberculosis (MIC = 16 µg/ml). It also reduces the growth of the disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), inhibits influenza A replication (EC50s = 0.3-1 μM), and inhibits hepatitis B and hepatitis C virus replication (EC50 = 0.15 μM for both).{19984,19985,19983}
Brand:CaymanSKU:28533 - 1 mgAvailable on backorder
Toll-like receptor 4 (TLR4) is activated by lipopolysaccharide (LPS), with LPS-binding protein, to initiate an innate immune response, which typically includes increased expression of TNFα.{28195} TLR4-C34 is a 2-acetamidopyranoside that inhibits TLR4 signaling in enterocytes and macrophages in vitro when used at 10 µM.{29731,29732} It does not affect signaling through either TLR2 or TLR9. TLR4-C34, used at 1 mg/kg in vivo, also reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.{29731} It markedly decreases the basal expression of TNFα, as well as LPS-induced iNOS and TNFα expression, in intestinal tissue isolated from patients with necrotizing enterocolitis.{29731}
Brand:CaymanSKU:-Available on backorder
Toll-like receptor 4 (TLR4) is activated by lipopolysaccharide (LPS), with LPS-binding protein, to initiate an innate immune response, which typically includes increased expression of TNFα.{28195} TLR4-C34 is a 2-acetamidopyranoside that inhibits TLR4 signaling in enterocytes and macrophages in vitro when used at 10 µM.{29731,29732} It does not affect signaling through either TLR2 or TLR9. TLR4-C34, used at 1 mg/kg in vivo, also reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.{29731} It markedly decreases the basal expression of TNFα, as well as LPS-induced iNOS and TNFα expression, in intestinal tissue isolated from patients with necrotizing enterocolitis.{29731}
Brand:CaymanSKU:-Available on backorder
Toll-like receptor 4 (TLR4) is activated by lipopolysaccharide (LPS), with LPS-binding protein, to initiate an innate immune response, which typically includes increased expression of TNFα.{28195} TLR4-C34 is a 2-acetamidopyranoside that inhibits TLR4 signaling in enterocytes and macrophages in vitro when used at 10 µM.{29731,29732} It does not affect signaling through either TLR2 or TLR9. TLR4-C34, used at 1 mg/kg in vivo, also reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.{29731} It markedly decreases the basal expression of TNFα, as well as LPS-induced iNOS and TNFα expression, in intestinal tissue isolated from patients with necrotizing enterocolitis.{29731}
Brand:CaymanSKU:-Available on backorder
Toll-like receptor 4 (TLR4) is activated by lipopolysaccharide (LPS), with LPS-binding protein, to initiate an innate immune response, which typically includes increased expression of TNFα.{28195} TLR4-C34 is a 2-acetamidopyranoside that inhibits TLR4 signaling in enterocytes and macrophages in vitro when used at 10 µM.{29731,29732} It does not affect signaling through either TLR2 or TLR9. TLR4-C34, used at 1 mg/kg in vivo, also reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.{29731} It markedly decreases the basal expression of TNFα, as well as LPS-induced iNOS and TNFα expression, in intestinal tissue isolated from patients with necrotizing enterocolitis.{29731}
Brand:CaymanSKU:-Available on backorder
TLR agonist 2 is a toll-like receptor 7 (TLR7) agonist with a lowest effective concentration (LEC) value of 0.4 μM in a cell-based reporter assay.{54116} It is selective for TLR7 over TLR8 (LEC = >100 μM). TLR7 agonist 2 (0.3-10 mg/kg) increases IFN-α levels and the IFN-stimulated gene (ISG) response, increasing the expression of Oas1b, Isg15, and Mx1, in mouse liver and plasma. It increases plasma levels of IFN-α, CCL2, IL-6, IL-1Ra, G-CSF, and IL-10 in cynomolgus monkeys when administered at a dose of 10 mg/kg. TLR agonist 2 (0.3-5 mg/kg) reduces serum and liver viral load in the hydrodynamic injection (HDI) hepatitis B virus (HBV) mouse model.
Brand:CaymanSKU:28450 - 1 mgAvailable on backorder
TLR agonist 2 is a toll-like receptor 7 (TLR7) agonist with a lowest effective concentration (LEC) value of 0.4 μM in a cell-based reporter assay.{54116} It is selective for TLR7 over TLR8 (LEC = >100 μM). TLR7 agonist 2 (0.3-10 mg/kg) increases IFN-α levels and the IFN-stimulated gene (ISG) response, increasing the expression of Oas1b, Isg15, and Mx1, in mouse liver and plasma. It increases plasma levels of IFN-α, CCL2, IL-6, IL-1Ra, G-CSF, and IL-10 in cynomolgus monkeys when administered at a dose of 10 mg/kg. TLR agonist 2 (0.3-5 mg/kg) reduces serum and liver viral load in the hydrodynamic injection (HDI) hepatitis B virus (HBV) mouse model.
Brand:CaymanSKU:28450 - 10 mgAvailable on backorder
TLR agonist 2 is a toll-like receptor 7 (TLR7) agonist with a lowest effective concentration (LEC) value of 0.4 μM in a cell-based reporter assay.{54116} It is selective for TLR7 over TLR8 (LEC = >100 μM). TLR7 agonist 2 (0.3-10 mg/kg) increases IFN-α levels and the IFN-stimulated gene (ISG) response, increasing the expression of Oas1b, Isg15, and Mx1, in mouse liver and plasma. It increases plasma levels of IFN-α, CCL2, IL-6, IL-1Ra, G-CSF, and IL-10 in cynomolgus monkeys when administered at a dose of 10 mg/kg. TLR agonist 2 (0.3-5 mg/kg) reduces serum and liver viral load in the hydrodynamic injection (HDI) hepatitis B virus (HBV) mouse model.
Brand:CaymanSKU:28450 - 5 mgAvailable on backorder
TLR7/8 agonist 1 is a dual agonist of toll-like receptor 7 (TLR7) and TLR8 (EC50s = 50 and 55 nM, respectively, in cell-based assays).{47662} It increases the levels of TNF-α, IFN-γ, IL-12p40, and chemokine (C-C motif) ligand 4 (CCL4) in human peripheral blood mononuclear cells (PBMCs) in a biphasic manner. TLR7/8 agonist 1 (25 nmol, s.c.) increases serum levels of IL-12p40 and chemokine (C-X-C motif) ligand 10 (CXCL10), as well as the number of dendritic cells per injection-site proximal lymph node, in mice.{47663} It has been conjugated to various fluorophores as TLR7 probes and to polymer particles for the modulation of TLR7/8 agonist 1 adjuvant activity.{47664,47663}
Brand:CaymanSKU:28451 - 1 mgAvailable on backorder
TLR7/8 agonist 1 is a dual agonist of toll-like receptor 7 (TLR7) and TLR8 (EC50s = 50 and 55 nM, respectively, in cell-based assays).{47662} It increases the levels of TNF-α, IFN-γ, IL-12p40, and chemokine (C-C motif) ligand 4 (CCL4) in human peripheral blood mononuclear cells (PBMCs) in a biphasic manner. TLR7/8 agonist 1 (25 nmol, s.c.) increases serum levels of IL-12p40 and chemokine (C-X-C motif) ligand 10 (CXCL10), as well as the number of dendritic cells per injection-site proximal lymph node, in mice.{47663} It has been conjugated to various fluorophores as TLR7 probes and to polymer particles for the modulation of TLR7/8 agonist 1 adjuvant activity.{47664,47663}
Brand:CaymanSKU:28451 - 5 mgAvailable on backorder
TLR7/8 agonist 1 is a dual agonist of toll-like receptor 7 (TLR7) and TLR8 (EC50s = 50 and 55 nM, respectively, in cell-based assays).{47662} It increases the levels of TNF-α, IFN-γ, IL-12p40, and chemokine (C-C motif) ligand 4 (CCL4) in human peripheral blood mononuclear cells (PBMCs) in a biphasic manner. TLR7/8 agonist 1 (25 nmol, s.c.) increases serum levels of IL-12p40 and chemokine (C-X-C motif) ligand 10 (CXCL10), as well as the number of dendritic cells per injection-site proximal lymph node, in mice.{47663} It has been conjugated to various fluorophores as TLR7 probes and to polymer particles for the modulation of TLR7/8 agonist 1 adjuvant activity.{47664,47663}
Brand:CaymanSKU:28451 - 500 µgAvailable on backorder
TM5275 is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 6.95 µM), a serine-protease inhibitor involved in thrombosis.{39402} TM5275 inhibits formation of a complex consisting of tissue plasminogen activator (tPA), PAI-1, and GFP on vascular endothelial cells (VECs) in vitro, prolonging the time that tPA is retained on VECs.{39403} It also enhances fibrin clot dissolution and plasminogen accumulation in vitro and has antithrombotic effects in rat models of thrombosis.{39402} TM5275 (10 and 50 mg/kg) decreases blood clot weight in an arteriovenous shunt thrombosis model and increases the time to primary occlusion in a ferric chloride-treated carotid artery thrombosis model when used at doses of 1 and 3 mg/kg. In a cynomolgus monkey model of photochemical-induced arterial thrombosis, TM5275 (10 mg/kg) increases the time to primary occlusion. It does not affect platelet activity, activated partial thromboplastin time, prothrombin time, or prolong bleeding time.
Brand:CaymanSKU:23151 - 1 mgAvailable on backorder
TM5275 is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 6.95 µM), a serine-protease inhibitor involved in thrombosis.{39402} TM5275 inhibits formation of a complex consisting of tissue plasminogen activator (tPA), PAI-1, and GFP on vascular endothelial cells (VECs) in vitro, prolonging the time that tPA is retained on VECs.{39403} It also enhances fibrin clot dissolution and plasminogen accumulation in vitro and has antithrombotic effects in rat models of thrombosis.{39402} TM5275 (10 and 50 mg/kg) decreases blood clot weight in an arteriovenous shunt thrombosis model and increases the time to primary occlusion in a ferric chloride-treated carotid artery thrombosis model when used at doses of 1 and 3 mg/kg. In a cynomolgus monkey model of photochemical-induced arterial thrombosis, TM5275 (10 mg/kg) increases the time to primary occlusion. It does not affect platelet activity, activated partial thromboplastin time, prothrombin time, or prolong bleeding time.
Brand:CaymanSKU:23151 - 10 mgAvailable on backorder
TM5275 is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 6.95 µM), a serine-protease inhibitor involved in thrombosis.{39402} TM5275 inhibits formation of a complex consisting of tissue plasminogen activator (tPA), PAI-1, and GFP on vascular endothelial cells (VECs) in vitro, prolonging the time that tPA is retained on VECs.{39403} It also enhances fibrin clot dissolution and plasminogen accumulation in vitro and has antithrombotic effects in rat models of thrombosis.{39402} TM5275 (10 and 50 mg/kg) decreases blood clot weight in an arteriovenous shunt thrombosis model and increases the time to primary occlusion in a ferric chloride-treated carotid artery thrombosis model when used at doses of 1 and 3 mg/kg. In a cynomolgus monkey model of photochemical-induced arterial thrombosis, TM5275 (10 mg/kg) increases the time to primary occlusion. It does not affect platelet activity, activated partial thromboplastin time, prothrombin time, or prolong bleeding time.
Brand:CaymanSKU:23151 - 25 mgAvailable on backorder
TM5275 is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 6.95 µM), a serine-protease inhibitor involved in thrombosis.{39402} TM5275 inhibits formation of a complex consisting of tissue plasminogen activator (tPA), PAI-1, and GFP on vascular endothelial cells (VECs) in vitro, prolonging the time that tPA is retained on VECs.{39403} It also enhances fibrin clot dissolution and plasminogen accumulation in vitro and has antithrombotic effects in rat models of thrombosis.{39402} TM5275 (10 and 50 mg/kg) decreases blood clot weight in an arteriovenous shunt thrombosis model and increases the time to primary occlusion in a ferric chloride-treated carotid artery thrombosis model when used at doses of 1 and 3 mg/kg. In a cynomolgus monkey model of photochemical-induced arterial thrombosis, TM5275 (10 mg/kg) increases the time to primary occlusion. It does not affect platelet activity, activated partial thromboplastin time, prothrombin time, or prolong bleeding time.
Brand:CaymanSKU:23151 - 5 mgAvailable on backorder
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor 1 (PAI-1), a serine-protease inhibitor involved in thrombosis.{37397,37395} It decreases survival of HT1080, HCT116, Daoy, MDA-MB-231, and Jurkat cancer cells with IC50 values ranging from 13.9 to 51.1 µM.{37397} TM5441 inhibits branching of human umbilical vein endothelial cells (HUVECs) in a vasculature assay in vitro when used at a concentration of 50 µM but does not affect HUVEC survival or apoptosis. It also disrupts tumor vasculature in HT1080 and HCT116 mouse xenograft models when used at a dose of 20 mg/kg per day. TM5441 prevents hypertension and cardiac hypertrophy and reduces periaortic fibrosis induced by L-NAME (Item No. 80210).{37395} It protects against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice when administered concurrently with a high-fat diet or after glucose tolerance has developed.{37398} TM5441 also increases median lifespan by 4-fold and reduces signs of senescence in Klotho-deficient mice, a mouse model of aging.{37396}
Brand:CaymanSKU:22965 - 1 mgAvailable on backorder
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor 1 (PAI-1), a serine-protease inhibitor involved in thrombosis.{37397,37395} It decreases survival of HT1080, HCT116, Daoy, MDA-MB-231, and Jurkat cancer cells with IC50 values ranging from 13.9 to 51.1 µM.{37397} TM5441 inhibits branching of human umbilical vein endothelial cells (HUVECs) in a vasculature assay in vitro when used at a concentration of 50 µM but does not affect HUVEC survival or apoptosis. It also disrupts tumor vasculature in HT1080 and HCT116 mouse xenograft models when used at a dose of 20 mg/kg per day. TM5441 prevents hypertension and cardiac hypertrophy and reduces periaortic fibrosis induced by L-NAME (Item No. 80210).{37395} It protects against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice when administered concurrently with a high-fat diet or after glucose tolerance has developed.{37398} TM5441 also increases median lifespan by 4-fold and reduces signs of senescence in Klotho-deficient mice, a mouse model of aging.{37396}
Brand:CaymanSKU:22965 - 10 mgAvailable on backorder
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor 1 (PAI-1), a serine-protease inhibitor involved in thrombosis.{37397,37395} It decreases survival of HT1080, HCT116, Daoy, MDA-MB-231, and Jurkat cancer cells with IC50 values ranging from 13.9 to 51.1 µM.{37397} TM5441 inhibits branching of human umbilical vein endothelial cells (HUVECs) in a vasculature assay in vitro when used at a concentration of 50 µM but does not affect HUVEC survival or apoptosis. It also disrupts tumor vasculature in HT1080 and HCT116 mouse xenograft models when used at a dose of 20 mg/kg per day. TM5441 prevents hypertension and cardiac hypertrophy and reduces periaortic fibrosis induced by L-NAME (Item No. 80210).{37395} It protects against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice when administered concurrently with a high-fat diet or after glucose tolerance has developed.{37398} TM5441 also increases median lifespan by 4-fold and reduces signs of senescence in Klotho-deficient mice, a mouse model of aging.{37396}
Brand:CaymanSKU:22965 - 5 mgAvailable on backorder
TMA-DPH is a fluorescent probe used for measuring membrane fluidity in artificial and living membrane systems.{28346,28344,28345,28343} The cylindrical shape of TMA-DPH confers high sensitivity to reorientation resulting from changes in surrounding lipids. TMA-DPH has excitation and emission maxima at 355 and 430 nm, respectively.
Brand:CaymanSKU:-Available on backorder
TMA-DPH is a fluorescent probe used for measuring membrane fluidity in artificial and living membrane systems.{28346,28344,28345,28343} The cylindrical shape of TMA-DPH confers high sensitivity to reorientation resulting from changes in surrounding lipids. TMA-DPH has excitation and emission maxima at 355 and 430 nm, respectively.
Brand:CaymanSKU:-Available on backorder
TMA-DPH is a fluorescent probe used for measuring membrane fluidity in artificial and living membrane systems.{28346,28344,28345,28343} The cylindrical shape of TMA-DPH confers high sensitivity to reorientation resulting from changes in surrounding lipids. TMA-DPH has excitation and emission maxima at 355 and 430 nm, respectively.
Brand:CaymanSKU:-Available on backorder
TMB is an aromatic amine that undergoes oxidation by the higher oxidation states of heme peroxidases (compounds I and II) thereby serving as a reducing co-substrate. One electron oxidation of TMB results in a radical cation that forms a charge-transfer complex with the unoxidized compound. This charge transfer complex absorbs at 652 nm (ε = 39,000).{8111} The completely oxidized form (diimine) absorbs at 450 nm (ε = 59,000) and is formed by two sequential one-electron oxidations of TMB.{8111,8109} Thus the stoichiometry of oxidation is 0.5 mole charge transfer complex (λmax = 652 nm) or 1 mole of diimine (λmax = 450 nm) formed (or TMB oxidized) per mole of hydroperoxide reduced by the peroxidase.
Brand:CaymanSKU:70450 - 1 gAvailable on backorder
TMB is an aromatic amine that undergoes oxidation by the higher oxidation states of heme peroxidases (compounds I and II) thereby serving as a reducing co-substrate. One electron oxidation of TMB results in a radical cation that forms a charge-transfer complex with the unoxidized compound. This charge transfer complex absorbs at 652 nm (ε = 39,000).{8111} The completely oxidized form (diimine) absorbs at 450 nm (ε = 59,000) and is formed by two sequential one-electron oxidations of TMB.{8111,8109} Thus the stoichiometry of oxidation is 0.5 mole charge transfer complex (λmax = 652 nm) or 1 mole of diimine (λmax = 450 nm) formed (or TMB oxidized) per mole of hydroperoxide reduced by the peroxidase.
Brand:CaymanSKU:70450 - 100 mgAvailable on backorder
TMB is an aromatic amine that undergoes oxidation by the higher oxidation states of heme peroxidases (compounds I and II) thereby serving as a reducing co-substrate. One electron oxidation of TMB results in a radical cation that forms a charge-transfer complex with the unoxidized compound. This charge transfer complex absorbs at 652 nm (ε = 39,000).{8111} The completely oxidized form (diimine) absorbs at 450 nm (ε = 59,000) and is formed by two sequential one-electron oxidations of TMB.{8111,8109} Thus the stoichiometry of oxidation is 0.5 mole charge transfer complex (λmax = 652 nm) or 1 mole of diimine (λmax = 450 nm) formed (or TMB oxidized) per mole of hydroperoxide reduced by the peroxidase.
Brand:CaymanSKU:70450 - 250 mgAvailable on backorder
TMB is an aromatic amine that undergoes oxidation by the higher oxidation states of heme peroxidases (compounds I and II) thereby serving as a reducing co-substrate. One electron oxidation of TMB results in a radical cation that forms a charge-transfer complex with the unoxidized compound. This charge transfer complex absorbs at 652 nm (ε = 39,000).{8111} The completely oxidized form (diimine) absorbs at 450 nm (ε = 59,000) and is formed by two sequential one-electron oxidations of TMB.{8111,8109} Thus the stoichiometry of oxidation is 0.5 mole charge transfer complex (λmax = 652 nm) or 1 mole of diimine (λmax = 450 nm) formed (or TMB oxidized) per mole of hydroperoxide reduced by the peroxidase.
Brand:CaymanSKU:70450 - 5 gAvailable on backorder
TMB 8 is a non-competitive antagonist of nicotinic acetylcholine receptors (nAChRs) with IC50 values of 390 and 350 nM, respectively, for human muscle-type and α3β4 subunit-containing ganglionic nAChRs expressed in TE671/RD or SH-SY5Y cells.{38552} It inhibits nicotine-induced dopamine release from rat brain synaptosomes (IC50 = 480 nM). TMB 8 also reduces calcium availability in smooth and skeletal muscle, blocking the contractile response in isolated rabbit aortic strip when used at a concentration of 50 µM and inhibiting calcium influx and efflux in isolated guinea pig ileum when used at a concentration of 65 µM.{38553} It has been used in the study of intracellular calcium dynamics, particularly in smooth muscle.{38554,38555} TMB 8 also inhibits protein kinase C (PKC) activity in a dose-dependent manner.{38556}
Brand:CaymanSKU:23928 - 10 mgAvailable on backorder
TMB 8 is a non-competitive antagonist of nicotinic acetylcholine receptors (nAChRs) with IC50 values of 390 and 350 nM, respectively, for human muscle-type and α3β4 subunit-containing ganglionic nAChRs expressed in TE671/RD or SH-SY5Y cells.{38552} It inhibits nicotine-induced dopamine release from rat brain synaptosomes (IC50 = 480 nM). TMB 8 also reduces calcium availability in smooth and skeletal muscle, blocking the contractile response in isolated rabbit aortic strip when used at a concentration of 50 µM and inhibiting calcium influx and efflux in isolated guinea pig ileum when used at a concentration of 65 µM.{38553} It has been used in the study of intracellular calcium dynamics, particularly in smooth muscle.{38554,38555} TMB 8 also inhibits protein kinase C (PKC) activity in a dose-dependent manner.{38556}
Brand:CaymanSKU:23928 - 5 mgAvailable on backorder
TMC207 is a diarylquinoline that selectively inhibits the proton pump of the mycobacterial ATP synthase.{31976} It demonstrates potent activity against both drug-sensitive and drug-resistant M. tuberculosis and other mycobacterial species with MIC50 values of ~0.03 µg/ml.{31976}
Brand:CaymanSKU:20247 -Available on backorder
TMC207 is a diarylquinoline that selectively inhibits the proton pump of the mycobacterial ATP synthase.{31976} It demonstrates potent activity against both drug-sensitive and drug-resistant M. tuberculosis and other mycobacterial species with MIC50 values of ~0.03 µg/ml.{31976}
Brand:CaymanSKU:20247 -Available on backorder
TMC207 is a diarylquinoline that selectively inhibits the proton pump of the mycobacterial ATP synthase.{31976} It demonstrates potent activity against both drug-sensitive and drug-resistant M. tuberculosis and other mycobacterial species with MIC50 values of ~0.03 µg/ml.{31976}
Brand:CaymanSKU:20247 -Available on backorder